Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio (NASDAQ:GOSS), a late-stage clinical biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.

Cantor Global Healthcare Conference
Date / Time:	September 3rd, at 9:10 AM ET
Format:	Fireside Chat & 1x1’s
Location:	New York, NY
Webcast Link:	https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=93028624&checkCompany=1&checkEmail=1&checkName=1

Wells Fargo Healthcare Conference
Date / Time:	September 4th
Format:	1x1’s
Location:	Boston, MA

H.C. Wainwright 27th Annual Global Healthcare
Date / Time:	September 9th, at 8:00 AM ET
Format:	Fireside Chat & 1x1’s
Location:	New York, NY

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250829692001/en/

For Investors and Media
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Source: Gossamer Bio, Inc.